Yufan Zhao

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Tara C. Mitchell, Omid Hamid, David C. Smith et al. · Journal of Clinical Oncology · 2018 · 378 citations · Full text

Reinforcement learning design for cancer clinical trials

Yufan Zhao, Michael R. Kosorok, Donglin Zeng · Statistics in Medicine · 2009 · 276 citations · Full text

Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer

Yufan Zhao, Donglin Zeng, Mark A. Socinski et al. · Biometrics · 2011 · 215 citations

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Rebecca Kristeleit, Vadim Shirinkin, Fatima El-Khouly et al. · Gynecologic Oncology · 2017 · 100 citations

Medicine, Gynecology, Pathology +9

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

Geoffrey T. Gibney, Omid Hamid, Jose Lutzky et al. · Journal for ImmunoTherapy of Cancer · 2019 · 80 citations · Full text

Immunology, Melanoma Treatment Landscape, Pharmacotherapy +19